BioInvent International Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

BioInvent International şirketinin toplam hissedar öz sermayesi SEK1.0B ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK1.1B ve SEK84.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 950.11m
Eşitlik	SEK 1.00b
Toplam yükümlülükler	SEK 84.38m
Toplam varlıklar	SEK 1.09b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BIX0 'nin kısa vadeli varlıkları ( SEK1.0B ) kısa vadeli yükümlülüklerini ( SEK76.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: BIX0 şirketinin kısa vadeli varlıkları ( SEK1.0B ) uzun vadeli yükümlülüklerini ( SEK8.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BIX0 borçsuzdur.

Borcun Azaltılması: BIX0 son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BIX0 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: BIX0 serbest nakit akışı her yıl % 17.9 2.6 yıl yetecek nakit akışına sahip olacaktır.

BioInvent International Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Insufficient new directors

New minor risk - Revenue size

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma

Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

Second quarter 2024 earnings released: kr2.09 loss per share (vs kr1.34 loss in 2Q 2023)

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024

BioInvent International Gains Patent for BI-1808 in China

BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024

Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL

First quarter 2024 earnings released: kr1.18 loss per share (vs kr1.12 loss in 1Q 2023)

BioInvent International AB (publ) to Report Nine Months, 2024 Results on Oct 31, 2024

BioInvent International AB (publ), Annual General Meeting, May 03, 2024

Full year 2023 earnings released: kr5.02 loss per share (vs kr0.69 loss in FY 2022)

BioInvent International AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024

New minor risk - Market cap size

BioInvent International AB (publ) Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607

Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910

BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent

BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910

Third quarter 2023 earnings released: kr1.08 loss per share (vs kr1.00 loss in 3Q 2022)

Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors

Independent Director recently bought €51k worth of stock

Second quarter 2023 earnings released: kr1.34 loss per share (vs kr2.86 profit in 2Q 2022)

New minor risk - Market cap size

Independent Chairman of the Board recently bought €16k worth of stock

BioInvent International AB (publ) Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023

BioInvent International AB Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent Ready for Combination Studies with BT-001

BioInvent International AB (Publ) Appoints of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs

High number of new directors

Forecast to breakeven in 2025

Full year 2022 earnings released

Full year 2022 earnings released: kr0.69 loss per share (vs kr5.14 loss in FY 2021)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

BioInvent International AB (publ), Annual General Meeting, Apr 27, 2023

Bioinvent International AB Provides Update on Its Clinical and Pre-Clinical Pipeline, Including an Update on Its Lead Drug Candidate, the Novel Anti-Fc?RIIB Antibody Bi-1206

BioInvent International AB (publ) Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607

Third quarter 2022 earnings released: kr1.00 loss per share (vs kr1.07 loss in 3Q 2021)

Forecast to breakeven in 2024

BioInvent International AB (publ) Completes Dose Escalation Part of the Phase I/IIa Study with Anti-TNFR2 Drug Candidate BI-1808

CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China

BioInvent International AB (publ) to Report Q2, 2023 Results on Aug 30, 2023

BioInvent International AB (publ) to Report Q1, 2023 Results on Apr 26, 2023

Forecast to breakeven in 2024

Second quarter 2022 earnings released: EPS: kr2.86 (vs kr0.98 loss in 2Q 2021)

BioInvent International AB (publ) Enrolls First Patient in Phase 1/2A Trial of Bi-1607 in HER2 Positive Solid Tumors

Bioinvent International Resolves to Elect Natalie Berner and Nanna Lüneborg as New Board Members

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Bioinvent International AB (Publ) Appoints Sylvie Ryckebusch as Chief Business Officer

Forecast to breakeven in 2023

First quarter 2022 earnings released: kr1.16 loss per share (vs kr1.94 loss in 1Q 2021)

Full year 2021 earnings released: kr5.14 loss per share (vs kr2.66 loss in FY 2020)

President & CEO recently bought €23k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioInvent International AB (publ) to Report Q3, 2022 Results on Oct 27, 2022

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

BioInvent International AB (publ)(OM:BINV) dropped from OMX Nordic Small Cap Index

Independent Director recently bought €74k worth of stock

BioInvent International AB (publ) Announces Positive Early Data from Ongoing Solid Cancer Trial of BI-1206 in Combination with Pembrolizumab

Bioinvent International Announces Updated Positive Interim Top-Line Data from Its Novel Anti-FcyRIIB Antibody Bi-1206

Bioinvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China

BioInvent International AB Submits Clinical Trial Application for a Phase 1/2a trial of BI-1607

Third quarter 2021 earnings released: kr1.07 loss per share (vs kr1.00 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.98 loss per share (vs kr2.00 loss in 2Q 2020)

BioInvent International AB (publ) Receives Notice of Allowance in China for BI-1206 Patent

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

First quarter 2021 earnings released: kr1.94 loss per share (vs kr1.75 loss in 1Q 2020)

Full year 2020 earnings released: kr2.66 loss per share (vs kr7.64 loss in FY 2019)

Bioinvent Presents Proof-Of-Concept Data on Anti-Fcyriib Antibody Bi-1607 At Aacr Annual Meeting 2021